Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial (CONCEPTT)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01788527 |
|
Recruitment Status :
Completed
First Posted : February 11, 2013
Last Update Posted : July 19, 2017
|
Sponsor:
Mount Sinai Hospital, Canada
Collaborators:
Sunnybrook Research Institute
Jaeb Center for Health Research
Cambridge University Hospitals NHS Foundation Trust
University of Cambridge
Information provided by (Responsible Party):
Mount Sinai Hospital, Canada
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The primary objective of the study is to determine if RT CGM (Real Time-Continuous Glucose Monitoring) can improve glycemic control in women with T1D who are pregnant or planning pregnancy.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Type 1 Diabetics Who Are Pregnant or Planning Pregnancy | Device: CGM | Not Applicable |
In women with diabetes, hyperglycemia is associated with increased rates of numerous maternal and fetal adverse outcomes. Mothers are at increased risk of preeclampsia, polyhydramnios, and caesarean sections. Infants of mothers with diabetes have increased rates of congenital anomalies, premature delivery, macrosomia, stillbirth and NICU admissions. Macrosomia itself is associated with numerous adverse fetal outcomes including shoulder dystocia, birth injury, neonatal hypoglycemia, hyperbilirubinemia, respiratory distress syndrome and NICU admissions, asphyxia and death. Postprandial blood sugars in particular have been associated with increased macrosomia rates.
Numerous studies have shown that pregnancy outcomes can be reduced with improved glycemic control. In particular, pre-pregnancy care has been shown to assist women improve glucose control during the crucial period of organogenesis, and is associated with reduced rates of adverse pregnancy outcome including major congenital malformation, stillbirth and neonatal death.
Technological advances aimed at reducing glycemic excursions and improving glucose control in patients with diabetes include the continuous glucose monitoring (CGM) system. We hypothesize that real-time CGM will assist women with type 1 diabetes to improve their glycemic control before and during pregnancy.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 325 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial |
| Study Start Date : | March 2013 |
| Actual Primary Completion Date : | March 2016 |
| Actual Study Completion Date : | March 2016 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Dextrose
| Arm | Intervention/treatment |
|---|---|
|
Experimental: CGM
Continuous Glucose Monitoring
|
Device: CGM
Real Time Continuous Glucose Monitoring |
|
No Intervention: HGM
Standard of care, Home Glucose Monitoring
|
Primary Outcome Measures :
- Glycemic Control in pre-pregnant group [ Time Frame: 24 weeks or at conception ]Glycemic control as measured by HbA1c at 24 weeks or at conception. If the patient becomes pregnant, than a HbA1c will be measured post-confirmation of a positive pregnancy test and will contribute to the primary outcome.
- Glycemic Control in pregnant group [ Time Frame: 34 weeks gestation ]Glycemic control as measured by HbA1c at 34 weeks gestation. In women who do not progress to 34 weeks gestation, the latest measured HbA1c will be used to contribute to the primary outcome.
Secondary Outcome Measures :
- Time in target in pre-pregnant group [ Time Frame: 12 and 24 weeks after randomization ]Time in target at 12 and 24 weeks after randomization
- HbA1c and time in target, in pre-pregnant group who became pregnant within 24 weeks from randomization [ Time Frame: 24 weeks and 34 weeks gestation ]HbA1c and Time in target at post-confirmation of a positive pregnancy test, 24 weeks and 34 weeks gestation for those who start pre-pregnant and become pregnant
- Time in target in pregnant group [ Time Frame: Randomization, 24 weeks and 34 weeks gestation ]Time in target at randomization, 24 weeks and 34 weeks gestation
- HbA1c measurement in pregnant group [ Time Frame: 24 weeks and 34 weeks gestation ]HbA1c at randomization, 24 weeks and 34 weeks gestation
- Hypertension in pregnant group [ Time Frame: Up to 42 weeks gestation ]Incidence of worsening chronic hypertension, gestational hypertension, preeclampsia; total and individual measures
- Caesarean sections in pregnant group [ Time Frame: At delivery ]Caesarean section: primary and total
- Gestational weight gain in pregnant group [ Time Frame: Up to 34 weeks gestation ]Entry to 34 weeks gestation; 16 weeks to 34 weeks gestation
- AUC [ Time Frame: At delivery ]Area under the curve for blood sugars (a) >7.8 mmol/l or 140 mg/dl (b)>6.7 mmol/l or 120 mg/dl (c) <3.5 mmol/L or <63 mg/dl (d) <2.8 mmol/L or <50 mg/dl
- Incidence of Clinical events [ Time Frame: Up to 42 weeks gestation ]Episodes of 'severe hypoglycemia' requiring assistance; mild-moderate episodes of hypoglycemia <3.5 (mild) and <2.8 (moderate) from CGM data defined as AUC <3.5 or AUC less than or equal to 2.8 for 20 minutes duration; nocturnal hypoglycemia (NH) defined as CGM glucose <3.5 (mild) and <2.8 (moderate) between the hours of 23.00-07.00
- Glucose variability [ Time Frame: Up to delivery ]Mean amplitude of glycemic excursions (MAGE); Coefficient of Variation (CV); Standard deviation (SD) of CGM measurements; mean absolute rate of change of CGM based on one week of sensor values
- Hospital stay [ Time Frame: Admission until hospital discharge ]Length of hospital stay
- Infant Outcomes [ Time Frame: At birth of infant ]Infant birthweight >90th centile using customized growth curves; infant birthweight <10th centile using customized growth curves; infant birthweight >=4kg
- Infant Outcomes [ Time Frame: =<28 days of life ]Pregnancy loss (Miscarriage, stillbirth, neonatal death)
- Infant Outcomes [ Time Frame: At birth ]Preterm delivery (<37 weeks and early preterm <34 weeks)
- Infant Outcomes [ Time Frame: Until hospital discharge ]Birth injury
- Infant outcomes [ Time Frame: Until hospital discharge ]Shoulder dystocia
- Infant outcomes [ Time Frame: Until hospital discharge ]Neonatal hypoglycemia with intravenous dextrose
- Infant Outcomes [ Time Frame: Within first 7 days of life ]Hyperbilirubinemia
- Infant Outcomes [ Time Frame: Within first 7 days of life ]Respiratory Distress Syndrome (RDS)
- Infant Outcomes [ Time Frame: Until hospital discharge ]NICU admission > 24 hrs
- Infant Outcomes [ Time Frame: At birth ]Cord blood gas pH <7.0
- Infant Outcomes [ Time Frame: At birth ]Hyperinsulinemia (using Cord C-peptide)
- Infant Outcomes [ Time Frame: Within first 7 days of life or until hospital discharge (whichever is last) ]Composite fetal outcome: pregnancy loss:miscarriage, stillbirth, neonatal death (death<=28 days of life), birth injury, neonatal hypoglycemia, hyperbilirubinemia, respiratory distress syndrome requiring therapy, NICU admission >24 hours
- Infant Outcomes [ Time Frame: Within first 3 days of life ]Sum of skinfolds >90th percentile for gestational age
- Infant Outcomes [ Time Frame: Within first 3 days of life ]Other anthropometric measures
- Infant Outcomes [ Time Frame: Until hospital discharge ]Length of hospital stay
- Insulin requirements [ Time Frame: Pre-pregnant (randomization, 12 weeks, 24 weeks); Pregnant (randomization, 24 weeks and 34 weeks gestation) ]Units per kg per day
- Questionnaires [ Time Frame: Baseline and 24 weeks or at confirmed pregnancy (pre-pregnant); Baseline and 34 weeks (pregnant) ]BGMSRQ, HFS, PAID, SF12, CGM-SAT; NWTSQ
- Study Contacts [ Time Frame: Up to delivery ]Scheduled and unscheduled visits
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 40 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Clinical diagnosis of type 1 diabetes and using daily insulin therapy for at least one year
- Age 18-40 years
- Insulin regimen involves either the use of an insulin pump or multiple daily injections of insulin (at least 3 shots per day). Subjects using premixed fixed doses of insulin at the time of enrolment will not be eligible. Insulin regimen must be stable for at least 4 weeks (i.e. on multiple insulin injections or on insulin pump) prior to randomization.
- No expectation that subject will be moving out of the area of the clinical center during the next year, unless the move will be to an area served by another study center
- Informed Consent Form signed by the subject
In addition, specific eligibility criteria apply to the respective groups:
Pre-pregnancy Group:
- Patients who are planning pregnancy and wish to optimise glycemic control before conception
Pregnancy Group:
- Pregnancy gestation ≤13 weeks, 6 days at time of randomization
- Live singleton fetus
- Dating ultrasound (US) done to confirm gestational age, viability and rule out multiples. Gestational age will be based on the last menstrual period (LMP) provided there is a ≤5 day discrepancy with US dates in the first trimester and ≤10 day discrepancy with US dates in the second trimester. If the dates from LMP are outside these limits, the US dates will be used as the best estimate of gestational age.
Exclusion Criteria:
- Type 2 diabetes
- Gestational diabetes
- Previous participation in the study
- Estimated GFR <60 ml/min/1.73
- The presence of a significant medical disorder or use of a medication such as oral glucocorticoids that in the judgment of the investigator will affect the wearing of the sensors or the completion of any aspect of the protocol.
If the investigator is uncertain whether the patient would be eligible; i.e. if the medical disorder would constitute an exclusion, the Steering Committee will be asked to make the decision.
- Inpatient psychiatric treatment in the past 6 months
- Subjects using premixed fixed doses of insulin at the time of enrolment
In addition, specific exclusion criteria apply to the respective groups:
Pre-pregnancy Group:
- HbA1c <7.0% or >10.0%
Pregnancy Group:
- HbA1c <6.5% or >10.0%
- Known current higher order pregnancies (twins, triplets, etc.) These women will be excluded as they have a higher rate of adverse outcomes and could lead to inequalities if they are unequally distributed between the groups.
- Known potentially major fetal anomaly (as per EUROCAT criteria).
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01788527
Locations
Show 31 study locations
Sponsors and Collaborators
Mount Sinai Hospital, Canada
Sunnybrook Research Institute
Jaeb Center for Health Research
Cambridge University Hospitals NHS Foundation Trust
University of Cambridge
Investigators
| Principal Investigator: | Denice Feig, MD | MOUNT SINAI HOSPITAL | |
| Principal Investigator: | Helen Murphy, MB BCh BAO FRACP MD | Cambridge University Hospital NHS Foundation Trust and University of Cambridge |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Mount Sinai Hospital, Canada |
| ClinicalTrials.gov Identifier: | NCT01788527 |
| Obsolete Identifiers: | NCT01734031 |
| Other Study ID Numbers: |
12-0037-A |
| First Posted: | February 11, 2013 Key Record Dates |
| Last Update Posted: | July 19, 2017 |
| Last Verified: | July 2017 |
Keywords provided by Mount Sinai Hospital, Canada:
|
Diabetes Type 1 CGM |
Continuous Glucose Monitor HGM HbA1c |
Additional relevant MeSH terms:
|
Pregnancy in Diabetics Diabetes, Gestational Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases |
Endocrine System Diseases Pregnancy Complications Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases |